Defendant Favorable
507 defendant favorable decisions from Delhi High Court.
Defendant Favorable Decisions
507 cases | Page 7 of 17
Vikas Gupta & Anr v.M/S Sahni Cosmetics
The Delhi High Court upheld a lower court's decision, confirming an injunction that allowed M/S Sahni Cosmetics to continue using the trademark 'NEHA' for face cream. The court prioritized the defendant's established prior use of the mark dating back to 2003 over the plaintiff's claims, despite arguments regarding regulatory compliance under the Drugs and Cosmetics Act. This decision underscores the importance of demonstrating long-standing market presence in trademark disputes.
M/S Gulab Oil And Food (Ahmedabad) Pvt. Ltd. v.Smt. Madhu Gupta
The Delhi High Court dismissed the appeal filed by M/S Gulab Oil And Food, upholding the District Judge's interim order that prohibited the appellant from trading and selling 'Gulab' Namkeen products. The court found a prima facie case for confusion between the marks, noting that consumers identify the plaintiff's products solely by asking for 'Gulab.' Furthermore, it held that since namkeen is an allied product to the registered goods (Gajak/Rewari), Section 29 of the Trade Marks Act was attracted, thus justifying the interim protection.
Astrazeneca Ab v.Intas Pharmaceuticals Limited, Alkem Laboratories Ltd., Zydus Healthcare Limited & Anr., Torrent Pharmaceuticals Limited, Micro Labs Limited, MSN Laboratories Private Limited, Eris Lifesciences Limited, USV Private Limited, Ajanta Pharma Limited
This Delhi High Court judgment addresses multiple appeals filed by AstraZeneca seeking interim relief to restrain various pharmaceutical companies from infringing its patents. The core issue revolved around whether AstraZeneca was entitled to an immediate injunction while the underlying suits for permanent injunction were pending. The court ultimately dismissed all nine appeals, finding no merit in the appellants' claims.
Merck Sharp And Dohme Corp. v.Sms Pharmaceuticals Limited
Merck Sharp And Dohme Corp. filed a suit seeking an injunction against Sms Pharmaceuticals Limited for infringing its patent on Sitagliptin, an anti-diabetic drug. The court initially granted an ex-parte ad interim injunction in favor of Merck. However, upon considering the defendant's request under Section 107A (Bolar exemption), the court modified the injunction to allow limited export of the API for research and development purposes.
Willowood Chemicals Pvt Ltd v.Indo-Swiss Chemicals Ltd & Anr.
The defendants filed an application seeking permission from the court to sell their existing stock of a fungicidal composition, which was previously restrained by an ex-parte injunction. The plaintiff strongly opposed this request, arguing that the defendants had continued manufacturing and selling the infringing product despite being aware of the patent rights and prior objections. The court dismissed the application.
M/S. Golden Tobie Private Limited v.M/S. Golden Tobacco Limited
M/S. Golden Tobie Private Limited filed a suit seeking permanent injunctions and damages against M/S. Golden Tobacco Limited, alleging wrongful cancellation of an exclusive trademark license agreement. The core dispute revolved around the interpretation and validity of the termination notices issued by the defendant. However, the court ultimately ruled that since the controversy primarily arose from contractual terms rather than statutory infringement, the matter was subject to arbitration as per the existing clause in the agreements.
Raaj Unocal Lubricants Limited v.Apple Energy Pvt Ltd & Anr.
This Delhi High Court judgment addressed a dispute concerning the trademarks 'UNOCAL' and related products. The plaintiff, Raaj Unocal Lubricants Limited, had previously obtained an ad interim anti-suit injunction restraining the defendants from proceeding with litigation in the United States. However, the court ultimately allowed the vacation of this injunction. The ruling emphasized that Indian courts should not restrain parties from seeking protection against perceived infringement in foreign jurisdictions unless those proceedings are oppressive or vexatious to the domestic case.
M/S Kamdhenu Limited v.M/S Aashiana Rolling Mills Ltd.
Kamdhenu Limited sued Aashiana Rolling Mills Ltd. alleging infringement of its registered design for steel bars featuring a double-ribbed surface pattern. The defendant challenged the validity of this registration, arguing that the design was merely a common feature found in industry standards and prior publications. The Delhi High Court ultimately ruled in favor of the defendant, finding that the plaintiff's design lacked novelty because it reflected established industry practices and known standards.
M/S Nutrica Pusti Healthcare Pvt. Ltd. v.M/S Morepen Laboratories Ltd.
The Delhi High Court dismissed the appeal filed by Nutrica Pusti Healthcare Pvt. Ltd., upholding the Commercial Court's interim injunction against Morepen Laboratories Ltd. The court found that the marks used by the appellants were deceptively similar to those of the respondents, particularly considering the pharmaceutical context and potential for consumer confusion. This judgment reinforces the strict application of trademark principles in the highly regulated pharma sector.
Dr.Reddys Laboratories Limited v.Eros International Media Limited And Anr.
Dr. Reddy's Laboratories sought an urgent interim injunction to prevent the release of a feature film, 'Haathi Mere Saathi,' alleging that its brand mark 'DRL' was being used in a derogatory manner within the movie plot. The Delhi High Court ultimately dismissed the plaintiff's application, finding that Dr. Reddy's failed to meet the three-pronged test for granting an injunction. The court held that the balance of convenience favored the defendants due to their substantial investment in the film production.
Diva Enterprises (P) Ltd v.Institute Of Medico Legal Publication (P) Ltd.
The appeal challenged the dismissal of the appellant's application under Section 8 of the Arbitration and Conciliation Act. The appellant argued that the contractual dispute, seeking damages and injunction, was arbitrable. However, the High Court held that since the reliefs sought were primarily based upon Intellectual Property Rights (IPR), the dispute was non-arbitrable.
Eli Lilly And Company v.Natco Pharma Limited
This case involved a suit for alleged patent infringement. The defendants filed applications seeking condonation of delay in filing their written statements, citing difficulties caused by the COVID-19 pandemic and general disruptions to legal processes. The court allowed these applications, condoning the delay.
Centrient Pharmaceuticals Netherlands B.V. v.Dalas Biotech Limited
The plaintiffs filed an application seeking discovery through interrogatories in a suit alleging infringement of their patent for Amoxicillin Trihydrate. The plaintiffs argued that the defendant's process description was ambiguous and evasive, hiding the use of immobilized enzymes and specific acids. However, the court dismissed the application, finding it amounted to a roving inquiry and stating that the issues could be addressed through cross-examination.
RB Health (Us) Llc v.Dabur India Limited
RB Health (US) LLC filed an application seeking an interim injunction against Dabur India Limited, alleging infringement of their registered soap bar design (No. 271671) and the tort of passing off through similar trade dress and taglines. The plaintiffs sought to prevent Dabur from manufacturing or selling a competing soap bar under the brand 'SANITIZE'. However, the Delhi High Court ultimately dismissed the application for an injunction, noting that such cases heavily depend on specific facts rather than merely analogical precedents.
Astrazeneca Ab & Anr. v.Torrent Pharmaceuticals Ltd., Micro Labs Limited, Zydus Healthcare Ltd., ERIS Lifesciences Ltd., USV Pvt. Ltd., MSN Laboratories Pvt. Ltd.
The plaintiffs sought permanent and temporary injunctions against various defendants for infringing their patents related to Dapagliflozin. The court found that the defendants had laid a credible challenge to the validity of the suit patent, leading the court to decline the grant of interim injunction.
Astrazeneca Ab & Anr. v.Alkem Laboratories Limited
Astrazeneca sued Intas Pharmaceuticals Limited and Alkem Laboratories Limited regarding two patents, IN 147 (genus) and IN 625 (species), covering the SGLT2 inhibitor Dapagliflozin (DAPA). The core dispute was whether DAPA, which is used to treat type-II diabetes, falls within the scope of the genus patent. The court ultimately dismissed the plaintiffs' applications.
Pm Diesels Pvt Ltd v.Thukral Mechanical Works And Ors
The Delhi High Court dismissed the petitioner's writ petition challenging an IPAB order that rejected its request to implead the original trademark assignor. The court held that since the petitioner was questioning both the initial registration and the subsequent assignment as potentially fraudulent, the assignor (M/s Jain Industries) should have been included from the outset. Given the passage of time, the High Court found it inappropriate to allow impleadment at this late stage, thereby upholding the IPAB's decision.
Indoco Remedies Ltd. v.Bristol Myers Squibb Holdings Ireland Unlimited Company
Indoco Remedies Ltd. filed an application seeking permission to sell approximately 58,000 strips of its generic product APIXABID (Apixaban), which had been manufactured prior to a restrictive injunction being passed by the Single Judge. The court dismissed the application, holding that without a decision on the merits, it could not reverse the findings of the learned Single Judge.
Shogun Organics Ltd v.Gaur Hari Guchhait & Ors.
The suit was originally filed by Shogun Organics Ltd seeking permanent injunction against infringement of its process patent (IN236630) related to D-TRANS ALLETHRIN. The current application sought permission to sell existing manufactured stock prior to the final judgment. The court allowed the sale but directed the defendants to pay 5% of the sales value and deposit costs.
Monsanto Holdings Private Limited v.Competition Commission Of India
Monsanto Holdings Private Limited challenged several orders issued by the Competition Commission of India (CCI) concerning allegations of unfair trade practices related to the 'trait fee' charged for using Bt. Cotton technology. The core dispute revolved around the licensing terms and recurring fees imposed by MMBL, a subsidiary in India. The Delhi High Court dismissed the petitions, finding no reason to interfere with the CCI's administrative orders, provided they were not arbitrary or unreasonable.
Sungro Seeds Ltd v.Sk Tripathi & Ors
Sungro Seeds Ltd filed a suit alleging that its ex-employees misappropriated confidential information, including parent lines and breeding strategies for its hybrid cauliflower 'Katreena', which was then used by a competitor to market an identical variety named 'Riya'. The core dispute centered on the unauthorized use of trade secrets and unfair competition. However, the Delhi High Court ultimately dismissed the suit, holding that without prior registration under the Protection of Plant Varieties and Farmers' Rights Act, 2001 (PPVFR Act), the plaintiff could not maintain a suit to restrain infringement.
Prof. Dr. Claudio De Simone & Next Gen Pharma India Pvt. Ltd. v.Actial Farmaceutica Srl. (Formerly known as CD Investment Srl.) & Ors.
The plaintiffs, claiming ownership over the 'De Simone Formulation' through patent rights and subsequent Know-How agreements, filed suit against CD Group entities. The core dispute revolved around whether the plaintiff retained proprietary rights (trade secrets) after the initial patent expired in 2015. The court ultimately dismissed the suit, holding that without a valid patent right in India, the plaintiffs lacked a personal cause of action to restrain the defendants from working or selling the formulation.
D & H India Ltd v.Superon Schweisstechnik India Ltd
This appeal before the Delhi High Court concerned a suit filed by Superon Schweisstechnik India Ltd against D & H India Ltd, alleging infringement and passing off related to the trademark 'SUPERON'. The core legal dispute revolved around whether the respondent could amend its plaint to establish prior user rights for 'SUPERON' since 1994. The court ultimately upheld the Single Judge's decision, finding that allowing the amendment would not prejudice the appellant, who had ample opportunity to contest the claim.
Bharat Bhogilal Patel v.Nokia Corporations & Ors
The appellant filed a Regular First Appeal against a judgment decreeing the suit instituted by the respondent/plaintiff. The original suit declared that the processes and machinery used by the plaintiff did not infringe the appellant's patents (189027 and 188787) and granted permanent injunction restraining the appellant from threatening infringement proceedings. The appeal was dismissed primarily due to the failure of the appellant to prove sufficient cause for condoning the inordinate delay.
Genentech Inc And Others v.Drugs Controller General Of India And Others
This case involves an application by Defendant No. 3 seeking to restrict the participation of the plaintiffs' internal expert, Dr. Samir Sagitrao, in the inspection of confidential clinical and pre-clinical test data related to a biosimilar drug. The court ultimately dismissed the applicant's request, emphasizing that defendants have a right to defend the suit without being deprived of opportunity due to non-disclosure.
Central Park Estates Pvt. Ltd. v.Provident Housing Limited
The Delhi High Court dismissed the defendant's application seeking a three-month adjournment under Section 124 of the Trade Marks Act. The court emphasized that for this provision to apply, the defendant must explicitly plead in their formal pleadings that the plaintiff's trade mark is invalid. Despite the defendant raising indirect challenges to validity in other documents, the court held that the absence of a direct plea meant the statutory requirements were not met, thus denying the request for time to file a rectification petition.
Astrazeneca Ab v.Emcure Pharmaceuticals Limited
Astrazeneca sued Emcure Pharmaceuticals Limited and MSN Laboratories Limited for infringing their patents related to the pharmaceutical compound TICAGRELOR, marketed as BRILINTA. The plaintiffs sought an interim injunction against the defendants' generic versions (TICAPLAT and TIARE).
Sun Pharma Laboratories Ltd v.Intas Pharmaceuticals Ltd
The Delhi High Court dismissed Sun Pharma's appeal against a lower court order that denied an interim injunction. Sun Pharma sought protection for its registered trademark 'BEVETEX' against Intas Pharmaceuticals' use of 'BEVATAS,' alleging infringement and passing off in the pharmaceutical sector. The court found no prima facie case for infringement, noting that while both drugs are cancer treatments, their trade dress and administration methods were not remotely similar. Consequently, the appeal was dismissed.
M/S Parle Products Pvt Ltd & Anr. v.M/S B&B Bake Pvt Ltd
The Delhi High Court overturned an injunction restraining the appellant from using 'AMERICANA' for butter cookies. The court held that since 'AMERICANA' is a common dictionary word, its legal protectability is lesser, especially when it is not registered exclusively by the plaintiff. Furthermore, the court found no prima facie case of passing off because the products (cookies vs. burger buns) had distinct looks and packaging, making consumer confusion unlikely. The matter was remanded for further proceedings.
Gaur Hari Guchhait & Ors v.Shogun Organics Ltd
The appeal was filed by the original defendants against a decree that found them infringing the plaintiff's patent for the process of manufacturing d-trans Allethrin. The appellants argued that the process was already known due to its registration under the Insecticides Act, 1968. The court dismissed the appeal, holding that product registration does not equate to disclosure of the manufacturing process required for patentability.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.